Agios Pharma (AGIO) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Agios Pharma (AGIO) PT Raised to $90 at RBC Capital
May 7, 2018 7:39 AM EDTRBC Capital raised its price target on Agios Pharma (NASDAQ: AGIO) to $90.00 (from $88.00) while maintaining an Outperform rating.
Analsyt Kennen MacKay said came away from the R&D day more positive towards the company's internal pipeline and R&D engine. AGIO detailed the broad IDH... More



